NCT05291845RecruitingPhase 2
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts
Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts: Monotherapy Versus Combined Therapy
Source: ClinicalTrials.gov · Last updated 12 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 162 (estimated)
- First submitted
- 14 Mar 2022
- Start date
- 3 Apr 2022
- Primary completion date
- 3 Oct 2025
- Lead sponsor
- Zagazig University
- NCT number
- NCT05291845
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 162
- From 3 Apr 2022 to the primary completion date, 3 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine
Who the study is looking for
- patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study
Age in the registry: 9 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Reham Essam Coordinator of this site? Confirm its status | Zagazig | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.